Showing results (11-20 of 31) with videos related to

Sort By:
Pageof 4
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 7, 2015
Polymorphisms in MIR27A Associated with Early-Onset Toxicity in Fluoropyrimidine-Based ChemotherapyUrsula Amstutz, Steven M Offer, Johanna Sistonen, et al.
Pharmacogenomics|August 6, 2015
Dihydropyrimidinase and β-ureidopropionase gene variation and severe fluoropyrimidine-related toxicityDominic Kummer, Tanja K Froehlich, Markus Joerger, et al.
European Journal of Human Genetics : EJHG|September 2, 2004
Molecular diversity at the CYP2D6 locus in the Mediterranean regionSilvia Fuselli, Isabelle Dupanloup, Elena Frigato, et al.
Clinical Transplantation|October 14, 2015
Influence of CYP3A5 genetic variation on everolimus maintenance dosing after cardiac transplantationDorothea Lesche, Vilborg Sigurdardottir, Raschid Setoud, et al.
Pharmacogenetics and Genomics|June 4, 2010
Evolution of detoxifying systems: the role of environment and population history in shaping genetic diversity at human CYP2D6 locusSilvia Fuselli, Cesare de Filippo, Stefano Mona, et al.
Therapeutic Drug Monitoring|April 18, 2014
CYP3A5*3 and POR*28 genetic variants influence the required dose of tacrolimus in heart transplant recipientsDorothea Lesche, Vilborg Sigurdardottir, Raschid Setoud, et al.
Pharmacogenomics|November 21, 2014
Predicting 5-fluorouracil toxicity: DPD genotype and 5,6-dihydrouracil:uracil ratioJohanna Sistonen, Barbara Büchel, Tanja K Froehlich, et al.
Pharmacogenomics|September 24, 2010
Pharmacogenomics and active surveillance for serious adverse drug reactions in childrenTenneille T Loo, Colin J D Ross, Johanna Sistonen, et al.
Pain Research & Management|June 11, 2013
Life-threatening adverse events following therapeutic opioid administration in adults: is pharmacogenetic analysis useful?Parvaz Madadi, Johanna Sistonen, Gregory Silverman, et al.
Metabolomics : Official Journal of the Metabolomic Society|March 5, 2019
Targeted and global pharmacometabolomics in everolimus-based immunosuppression: association of co-medication and lysophosphatidylcholines with dose requirementDorothea Lesche, Vilborg Sigurdardottir, Alexander B Leichtle, et al.
Pageof 4